Page 173 - NobleCon20-Book-Project

Tonix Pharmaceuticals Holding Corp.

SELECTED FINANCIAL ITEMS TNXP

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue 3.78 2.48 2.21 2.82 11.29
Gross Profit 1.41 0.82 (1.16) 1.27 2.34
Gross Margin 37% 33% -52% 45% 21%
EBIT (27.33) (21.35) (18.36) (15.55) (82.59)
EBIT Margin -723% -860% -831% -551% -731%
Net Income to Common Shareholders (27.32) (14.94) (78.78) (14.21) (135.25)
Net Margin -723% -602% -3568% -504% -1198%

Balance Sheet Key Items
Total Assets 154.46 135.34 70.31 94.99 94.99
Cash & Short Term Investments 24.95 7.05 4.16 28.23 28.23
% of Assets 16% 5% 6% 30% 30%
Current Assets -Total 47.77 30.10 25.29 50.54 50.54
% of Assets 31% 22% 36% 53% 53%
Total Liabilities 48.93 27.20 28.20 20.78 20.78
% of Assets 32% 20% 40% 22% 22%
Current Liabilities - Total 18.88 20.48 22.04 NA NA
% of Assets 12% 15% 31% NM NM
Long Term Debt 6.56 6.16 5.67 NA NA
% of Assets 4% 5% 8% NM NM
Total Equity 105.53 108.14 42.10 74.21 74.21
% of Assets 68% 80% 60% 78% 78%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (22.34) (17.58) (9.92) NA (49.83)
Net Cash Flow - Investing (0.43) (0.11) 0.00 NA (0.54)
Net Cash Flow - Financing 40.71 (0.21) 7.03 NA 47.53

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference